When was Imlygic approved in Japan?
The provided information does not include Imlygic’s Japan approval date. If you share a source (package insert link, press release, or prescribing information page), I can extract the exact approval date from it.
What is Imlygic’s price in Japan?
The provided information does not include Imlygic pricing in Japan (including list price, reimbursement price, or patient out-of-pocket costs). If you share a Japan-specific pricing source (e.g., government drug price listing, reimbursement database entry, or a hospital/insurance posting), I can summarize the price details from that document.
What might users mean by “price” for Imlygic in Japan?
Japan drug “price” can show up in different forms, such as:
- official drug price (reimbursement/list price per vial),
- batch size / unit pricing differences by presentation,
- out-of-pocket cost after insurance,
- hospital dispensing or additional fees.
If you tell me which definition you need, I can format the answer accordingly once a source is available.
What else to check if you’re looking for Japan approval and pricing details
For immunotherapy products like Imlygic (talimogene laherparepvec), approvals and pricing can differ by:
- indication (e.g., unresectable melanoma vs other labels),
- product strength/presentation (vial concentration/volume),
- the time period of the listing (prices can change after revisions).
If you provide the presentation you mean, I can help you locate the matching price entry.
Sources
No sources were provided in the prompt.